What did @cassandra.crow actually say?
Cassandra didn't make a medical claim here. She asked her followers a simple question: "how much did you lose and how long did it take?" That's it. No dosing advice, no miracle promises, just crowd-sourcing personal results from other GLP-1 users. It's the kind of informal data collection that feels harmless but carries real context worth unpacking.
The framing is genuinely curious rather than promotional. She's collecting anecdotes, not citing trials. That matters when we evaluate what this kind of content does to audience expectations. When 198,000 people watch a comment thread fill up with weight loss numbers, they're building a mental average that may have nothing to do with what they'll personally experience.
Does the science back this up?
There's no specific claim to fact-check, but the implicit premise of the video, that GLP-1 results are comparable across users, is where the science pushes back hard.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks. But "average" is doing a lot of work in that sentence. The range in that trial was significant. Some participants lost over 20% of body weight. Others lost closer to 5%. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed even wider variation, with a mean of up to 22.5% at the highest dose, but again, individual results scattered broadly around that mean.
Genetics, baseline insulin resistance, gut microbiome composition, diet quality, sleep, and adherence all influence outcomes. No comment section will capture that complexity.
What did they get wrong (or right)?
Cassandra didn't get anything factually wrong because she didn't make a factual claim. That's worth crediting. She was transparent about her curiosity rather than presenting herself as an authority. She even corrected herself mid-sentence to include men: "girls or boys because I got a comment on my last video." Small thing, but it shows she's listening to her audience.
What's worth flagging isn't an error, it's a gap. Collecting anecdotal results without any anchor to clinical context creates a distorted picture for viewers. If most commenters share dramatic results, because people with dramatic results are more motivated to comment, the audience walks away with inflated expectations. Researchers call this survivorship bias, and it's rampant in weight loss content. A viewer who loses 6% of body weight on semaglutide might feel like they're failing when they're actually within a clinically meaningful range (Wing et al., 2011, Circulation defined 5-10% loss as clinically significant for cardiometabolic risk).
What should you actually know?
GLP-1 weight loss results are real but deeply personal. The clinical trials give us population averages, not predictions for any individual. Here's what the data actually tells us.
Timeline matters as much as total loss. Most participants in STEP trials hit their maximum weight loss around week 60-68. Expecting dramatic results in 8 weeks is a setup for discontinuation. Studies on GLP-1 adherence (Wharton et al., 2022, Obesity) show that a significant portion of users stop within the first year, often because results didn't match expectations set by social media.
- Average loss on semaglutide 2.4mg: roughly 15% of body weight over 68 weeks (Wilding et al., 2021)
- Average loss on tirzepatide 15mg: up to 22.5% over 72 weeks (Jastreboff et al., 2022)
- Weight typically returns after stopping: 66% regained within one year of discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism)
- 5-10% loss is clinically meaningful for heart and metabolic health, even if it looks modest on a comment thread
If you're comparing your progress to strangers on TikTok, you're using the wrong benchmark. Talk to a licensed clinician who can contextualize your results against your starting point, your health history, and your dose trajectory.